Close

Form 6-K Quoin Pharmaceuticals, For: Sep 30

November 10, 2022 11:09 AM EST
0001671502--12-312022Q32022-09-30000-00000false00016715022022-01-012022-09-300001671502qnrx:BridgeWarrantsCommonStockMember2021-09-300001671502us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2022-09-300001671502us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2022-09-300001671502us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001671502us-gaap:FairValueMeasurementsRecurringMember2022-09-300001671502us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberqnrx:Notes2020WarrantsMember2021-12-310001671502us-gaap:FairValueMeasurementsRecurringMemberqnrx:Notes2020WarrantsMember2021-12-310001671502us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001671502us-gaap:FairValueMeasurementsRecurringMember2021-12-3100016715022022-09-302022-09-3000016715022021-12-312021-12-310001671502qnrx:QuoinPharmaceuticalsIncMemberdei:AdrMemberqnrx:PublicOfferingMember2022-08-092022-08-090001671502qnrx:PublicOfferingMember2022-08-092022-08-090001671502qnrx:BridgeNotesMemberdei:AdrMember2022-07-012022-09-300001671502qnrx:ConvertibleNotesWarrantsCommonStockMemberqnrx:Convertiblenotes2020Member2021-03-012021-03-310001671502us-gaap:TreasuryStockCommonMember2022-09-300001671502us-gaap:RetainedEarningsMember2022-09-300001671502us-gaap:AdditionalPaidInCapitalMember2022-09-300001671502us-gaap:TreasuryStockCommonMember2022-06-300001671502us-gaap:RetainedEarningsMember2022-06-300001671502us-gaap:AdditionalPaidInCapitalMember2022-06-3000016715022022-06-300001671502us-gaap:TreasuryStockCommonMember2022-03-310001671502us-gaap:RetainedEarningsMember2022-03-310001671502us-gaap:AdditionalPaidInCapitalMember2022-03-3100016715022022-03-310001671502us-gaap:TreasuryStockCommonMember2021-12-310001671502us-gaap:RetainedEarningsMember2021-12-310001671502us-gaap:AdditionalPaidInCapitalMember2021-12-310001671502us-gaap:RetainedEarningsMember2021-09-300001671502us-gaap:AdditionalPaidInCapitalMember2021-09-300001671502us-gaap:RetainedEarningsMember2021-06-300001671502us-gaap:AdditionalPaidInCapitalMember2021-06-3000016715022021-06-300001671502us-gaap:RetainedEarningsMember2021-03-310001671502us-gaap:AdditionalPaidInCapitalMember2021-03-3100016715022021-03-310001671502us-gaap:RetainedEarningsMember2020-12-310001671502us-gaap:AdditionalPaidInCapitalMember2020-12-310001671502dei:AdrMemberqnrx:PublicOfferingMember2022-08-0900016715022021-01-012021-12-310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2022-03-012022-03-310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2021-01-012021-12-310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2021-12-310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2021-12-310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2022-07-012022-09-300001671502dei:AdrMember2021-01-012021-12-310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2022-01-012022-09-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2022-01-012022-09-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2022-04-120001671502srt:MinimumMemberqnrx:AmendedAndRestatedEquityIncentivePlanMember2022-04-122022-04-120001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2022-04-122022-04-120001671502qnrx:TherapeuticsInc.Memberus-gaap:ResearchAndDevelopmentArrangementMember2022-07-012022-09-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-07-012022-09-300001671502qnrx:NethertonSyndromeMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-07-012022-09-300001671502qnrx:AxellaResearchLlcMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-07-012022-09-300001671502qnrx:TherapeuticsInc.Memberus-gaap:ResearchAndDevelopmentArrangementMember2022-01-012022-09-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-01-012022-09-300001671502qnrx:NethertonSyndromeMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-01-012022-09-300001671502qnrx:AxellaResearchLlcMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-01-012022-09-300001671502qnrx:TherapeuticsInc.Memberus-gaap:ResearchAndDevelopmentArrangementMember2021-07-012021-09-300001671502qnrx:AxellaResearchLlcMemberus-gaap:ResearchAndDevelopmentArrangementMember2021-07-012021-09-300001671502qnrx:TherapeuticsInc.Memberus-gaap:ResearchAndDevelopmentArrangementMember2021-01-012021-09-300001671502qnrx:AxellaResearchLlcMemberus-gaap:ResearchAndDevelopmentArrangementMember2021-01-012021-09-300001671502qnrx:ConsultingExpenseMember2022-07-012022-09-300001671502qnrx:ConsultingExpenseMember2022-01-012022-09-300001671502qnrx:ConsultingExpenseMember2021-07-012021-09-300001671502qnrx:ConsultingExpenseMember2021-01-012021-09-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2022-07-012022-09-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2022-01-012022-09-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2021-07-012021-09-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2021-01-012021-09-300001671502qnrx:BridgeNotesThirdPurchaseMay2021Member2021-03-242021-03-240001671502qnrx:BridgeNotesSecondPurchaseApril2021Member2021-03-242021-03-240001671502qnrx:BridgeNotesFirstClosingMarch252021Member2021-03-242021-03-240001671502us-gaap:RetainedEarningsMember2022-04-012022-06-300001671502us-gaap:RetainedEarningsMember2022-01-012022-03-310001671502us-gaap:RetainedEarningsMember2021-07-012021-09-300001671502us-gaap:RetainedEarningsMember2021-04-012021-06-3000016715022021-04-012021-06-300001671502us-gaap:RetainedEarningsMember2021-01-012021-03-3100016715022021-01-012021-03-3100016715022020-02-012020-02-290001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2022-06-302022-06-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2022-03-012022-03-310001671502us-gaap:TechnologyBasedIntangibleAssetsMember2022-09-300001671502us-gaap:LicensingAgreementsMember2022-09-300001671502us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-310001671502us-gaap:LicensingAgreementsMember2021-12-310001671502qnrx:Notes2020WarrantsMember2021-12-310001671502qnrx:Notes2020WarrantsMember2021-01-012021-12-3100016715022022-07-142022-07-140001671502dei:AdrMember2022-01-012022-09-300001671502dei:AdrMember2021-07-012021-09-300001671502dei:AdrMember2021-01-012021-09-300001671502qnrx:SalariesAndOtherCompensationMember2022-09-300001671502qnrx:InvoicesPaidOnBehalfOfCompanyMember2022-09-300001671502qnrx:SalariesAndOtherCompensationMember2021-12-310001671502qnrx:InvoicesPaidOnBehalfOfCompanyMember2021-12-310001671502qnrx:Convertiblenotes2020Member2022-08-090001671502qnrx:BridgeNotesMember2022-08-090001671502us-gaap:CommonStockMember2022-09-300001671502us-gaap:CommonStockMember2022-06-300001671502dei:AdrMember2022-06-300001671502us-gaap:CommonStockMember2022-03-310001671502dei:AdrMember2022-03-310001671502us-gaap:CommonStockMember2021-12-310001671502us-gaap:CommonStockMember2021-09-300001671502dei:AdrMember2021-09-300001671502us-gaap:CommonStockMember2021-06-300001671502dei:AdrMember2021-06-300001671502us-gaap:CommonStockMember2021-03-310001671502dei:AdrMember2021-03-310001671502us-gaap:CommonStockMember2020-12-310001671502dei:AdrMember2020-12-310001671502dei:AdrMember2021-12-310001671502qnrx:QuoinPharmaceuticalsIncMemberus-gaap:SubsequentEventMember2022-11-020001671502us-gaap:SubsequentEventMember2022-11-020001671502qnrx:QuoinPharmaceuticalsIncMember2022-04-110001671502qnrx:QuoinPharmaceuticalsIncMemberus-gaap:SubsequentEventMember2022-11-030001671502us-gaap:SubsequentEventMember2022-11-030001671502qnrx:QuoinPharmaceuticalsIncMember2022-04-120001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2022-09-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2022-09-300001671502qnrx:AltiumMemberdei:AdrMember2022-08-0200016715022022-07-140001671502qnrx:Convertiblenotes2020Member2022-09-300001671502qnrx:BridgeWarrantsCommonStockSecondAndThirdClosingsMember2022-09-300001671502qnrx:BridgeWarrantsCommonStockFirstClosingMember2022-09-300001671502qnrx:SeriesBWarrantsAmericanDepositarySharesMember2022-03-130001671502qnrx:SeriesaWarrantsAmericanDepositarySharesMember2022-03-130001671502qnrx:ConvertibleNotesWarrantsCommonStockMember2021-12-310001671502qnrx:BridgeWarrantsCommonStockMember2021-12-310001671502qnrx:ConvertibleNotesWarrantsCommonStockMember2020-12-310001671502qnrx:PreFundedWarrantsMemberdei:AdrMemberqnrx:PublicOfferingMember2022-08-090001671502qnrx:PreFundedWarrantsMemberqnrx:PublicOfferingMember2022-08-090001671502dei:AdrMember2022-04-020001671502qnrx:ConvertibleNotesWarrantsCommonStockMemberqnrx:Convertiblenotes2020Member2022-09-300001671502qnrx:ExchangeWarrantsAmericanDepositarySharesMember2022-09-300001671502dei:AdrMember2022-09-300001671502qnrx:CommonWarrantsMemberdei:AdrMemberqnrx:PublicOfferingMember2022-08-090001671502dei:AdrMember2022-08-020001671502qnrx:AltiumMemberdei:AdrMemberqnrx:AltiumAgreementMember2022-07-140001671502qnrx:AltiumAgreementMember2022-07-140001671502qnrx:ConvertibleNotesWarrantsCommonStockMemberqnrx:Convertiblenotes2020Member2021-03-3100016715022021-09-3000016715022020-12-310001671502qnrx:SkinvisiblelicenseagreementMember2019-10-172019-10-170001671502qnrx:OutstandingWarrantsMemberdei:AdrMember2022-07-012022-09-300001671502qnrx:OutstandingWarrantsMember2022-07-012022-09-300001671502qnrx:OutstandingWarrantsMemberdei:AdrMember2022-01-012022-09-300001671502qnrx:OutstandingWarrantsMember2022-01-012022-09-300001671502us-gaap:WarrantMemberdei:AdrMember2021-07-012021-09-300001671502us-gaap:WarrantMember2021-07-012021-09-300001671502us-gaap:WarrantMemberdei:AdrMember2021-01-012021-09-300001671502us-gaap:WarrantMember2021-01-012021-09-300001671502us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001671502us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001671502us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001671502us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001671502us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100016715022022-01-012022-03-310001671502us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000016715022022-04-012022-06-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2021-12-310001671502qnrx:AxellaResearchLlcMemberqnrx:ConsultingAgreementMember2021-12-3100016715022022-08-092022-08-0900016715022022-08-102022-08-100001671502qnrx:BridgeNotesMemberus-gaap:PrivatePlacementMember2021-10-282021-10-280001671502qnrx:BridgeNotesMember2021-10-282021-10-280001671502us-gaap:CommonStockMember2022-07-012022-09-300001671502dei:AdrMember2022-07-012022-09-300001671502us-gaap:CommonStockMember2022-04-012022-06-300001671502dei:AdrMember2022-04-012022-06-300001671502us-gaap:CommonStockMember2022-01-012022-03-310001671502dei:AdrMember2022-01-012022-03-3100016715022022-08-012022-08-010001671502qnrx:SecuritiesPurchaseAgreementInPolytherapeuticsincMember2018-03-242018-03-240001671502us-gaap:PrivatePlacementMember2021-10-282021-10-280001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-09-300001671502srt:MinimumMember2022-08-010001671502srt:MaximumMember2022-08-010001671502dei:AdrMember2022-08-0100016715022021-12-012021-12-3100016715022021-11-012021-11-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2022-04-122022-04-120001671502qnrx:AxellaResearchLlcMemberqnrx:ConsultingAgreementMember2018-07-012018-07-310001671502qnrx:PreFundedWarrantsMemberdei:AdrMemberqnrx:PublicOfferingMember2022-08-092022-08-0900016715022021-10-282021-10-280001671502qnrx:OfficersAndFoundersMember2021-10-282021-10-280001671502dei:AdrMember2022-08-100001671502dei:AdrMember2022-06-100001671502qnrx:SeriesBWarrantsAmericanDepositarySharesSeriesCWarrantsExercisedInFullMember2022-03-132022-03-130001671502qnrx:SeriesaWarrantsAmericanDepositarySharesSeriesCWarrantsExercisedInFullMember2022-03-132022-03-1300016715022021-07-012021-09-300001671502qnrx:Notes2020WarrantsMember2022-01-012022-09-300001671502qnrx:BridgeFinancingWarrantsMember2021-01-012021-12-3100016715022022-07-012022-09-300001671502qnrx:BridgeNotesThirdPurchaseMay2021Member2021-03-240001671502qnrx:BridgeNotesSecondPurchaseApril2021Member2021-03-240001671502qnrx:BridgeNotesMember2021-03-240001671502qnrx:BridgeNotesFirstClosingMarch252021Member2021-03-240001671502qnrx:AxellaResearchLlcMemberus-gaap:ResearchAndDevelopmentArrangementMember2018-07-012018-07-310001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2022-09-300001671502qnrx:TherapeuticsInc.Memberqnrx:ConsultingAgreementMember2022-06-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-05-310001671502qnrx:NethertonSyndromeMemberqnrx:ConsultingAgreementMember2021-11-300001671502qnrx:PolytherapeuticsMemberus-gaap:ResearchAndDevelopmentArrangementMember2021-02-2800016715022021-01-012021-09-300001671502qnrx:BridgeWarrantsCommonStockMember2022-09-300001671502qnrx:SkinvisiblelicenseagreementMember2020-06-300001671502qnrx:SkinvisiblelicenseagreementMember2019-12-310001671502qnrx:AmendmentNumberThreeMemberqnrx:SkinvisiblelicenseagreementMember2021-01-270001671502qnrx:SkinvisiblelicenseagreementMember2021-01-270001671502qnrx:TherapeuticsInc.Memberqnrx:ConsultingAgreementMember2020-11-012020-11-300001671502us-gaap:RetainedEarningsMember2022-07-012022-09-300001671502us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001671502qnrx:SecuritiesPurchaseAgreementInPolytherapeuticsincMember2018-03-240001671502qnrx:SecuritiesPurchaseAgreementInPolytherapeuticsincMember2022-01-012022-09-300001671502qnrx:SecuritiesPurchaseAgreementInPolytherapeuticsincMember2021-01-012021-12-3100016715022022-09-3000016715022021-12-31iso4217:USDxbrli:pureqnrx:itemiso4217:USDxbrli:sharesqnrx:agreementxbrli:sharesqnrx:Yqnrx:Voteqnrx:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2022 (No. 2)

Commission File Number 001-37846

QUOIN PHARMACEUTICALS LTD.

(Translation of registrant’s name into English)

Azrieli Center, Round Tower, 30th Floor

132 Menachem Begin Blvd

Tel Aviv, 6701101

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXPLANATORY NOTE

Unaudited Interim Financial Statements as of, and for the period ended, September 30, 2022, and Related Management’s Discussion and Analysis of Financial Condition and Results of Operations

On November 10, 2022, Quoin Pharmaceuticals Ltd. (the “Company”) issued unaudited interim financial statements as of, and for the period ended, September 30, 2022, together with the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, attached hereto as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein.

The information in this Form 6-K, including the exhibits hereto, shall be incorporated by reference into the Company’s registration statements on Form S-8 (Registration Nos. 333-214817, 333-220015, 333-225003 and 333-232230,), and on Form F-3 (Registration Nos. 333-219614 and 333-229083).

Exhibits

Exhibit
No.

    

Exhibit

99.1

Unaudited Interim Financial Statements as of, and for the period ended, September 30, 2022

99.2

Management’s Discussion and Analysis of Financial Condition and Results of Operations as of, and for the period ended, September 30, 2022

101

Information formatted in Extensible Business Reporting Language (XBRL): (i) Unaudited Consolidated Balance Sheets, (ii) Unaudited Consolidated Statements of Operations, (iii) Unaudited Consolidated Statements of Shareholders’ Deficit, (iv) Unaudited Consolidated Statements of Cash Flows, and (v) Notes to Unaudited Consolidated Financial Statements.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 10, 2022

QUOIN PHARMACEUTICALS LTD.

By:

/s/ Gordon Dunn

Name:

Gordon Dunn

Title:

Chief Financial Officer

ATTACHMENTS / EXHIBITS

EX-99.1

EX-99.2

EX-101.SCH

EX-101.CAL

EX-101.DEF

EX-101.LAB

EX-101.PRE

IDEA: R1.htm

IDEA: R2.htm

IDEA: R3.htm

IDEA: R4.htm

IDEA: R5.htm

IDEA: R6.htm

IDEA: R7.htm

IDEA: R8.htm

IDEA: R9.htm

IDEA: R10.htm

IDEA: R11.htm

IDEA: R12.htm

IDEA: R13.htm

IDEA: R14.htm

IDEA: R15.htm

IDEA: R16.htm

IDEA: R17.htm

IDEA: R18.htm

IDEA: R19.htm

IDEA: R20.htm

IDEA: R21.htm

IDEA: R22.htm

IDEA: R23.htm

IDEA: R24.htm

IDEA: R25.htm

IDEA: R26.htm

IDEA: R27.htm

IDEA: R28.htm

IDEA: R29.htm

IDEA: R30.htm

IDEA: R31.htm

IDEA: R32.htm

IDEA: R33.htm

IDEA: R34.htm

IDEA: R35.htm

IDEA: R36.htm

IDEA: R37.htm

IDEA: R38.htm

IDEA: R39.htm

IDEA: R40.htm

IDEA: R41.htm

IDEA: R42.htm

IDEA: R43.htm

IDEA: R44.htm

IDEA: R45.htm

IDEA: R46.htm

IDEA: R47.htm

IDEA: R48.htm

IDEA: R49.htm

IDEA: R50.htm

IDEA: R51.htm

IDEA: R52.htm

IDEA: R53.htm

IDEA: R54.htm

IDEA: R55.htm

IDEA: R56.htm

IDEA: R57.htm

IDEA: R58.htm

IDEA: R59.htm

IDEA: R60.htm

IDEA: R61.htm

IDEA: R62.htm

IDEA: qnrx-20220930x6k_htm.xml

IDEA: Financial_Report.xlsx

IDEA: FilingSummary.xml

IDEA: MetaLinks.json



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings